[1] World Health Organization.Hepatitis B World Health Organization Fact sheet 204 dex(updated March 2015). WHO Website. http://www.who.int/mediacentre/factsheets/fs204/en/
[2] Locarnini S,Hatzakis A,Chen DS, et al. Strategies to control hepatitis B: Public policy, epidemiology,vaccine and drugs. J Hepatol, 2015,62:S76-S86.
[3] Lu FM,Zhuang H.Management of hepatitis B in China.Chin Med J (Engl), 2009, 122:3-4.
[4] Hawkes RA,Boughton CR,Ferguson V, et al. Use of immunoglobulin M antibody to hepatitis B core antigen in diagnosis of viral hepatitis. J Clin Microbiol, 1980,11:581-583.
[5] Lemon SM,Gates NL,Simms TE, et al. IgM antibody to hepatitis B core antigen as a diagnostic parameter of acute infection with hepatitis B virus. J Infect Dis, 1981,143:803-809.
[6] Gerlich WH,Uy A,Lambrecht F, et al. Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute,chronic,and past hepatitis B virus infections. J Clin Microbiol, 1986,24:288-293.
[7] Rodella A, Galli C,Terlenghi L, et al. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol, 2006,37:206-212.
[8] 中华医学会传染病与寄生虫病学分会,肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8:324-329.
[9] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南( 2015年更新版).临床肝胆病杂志,2015,31:1941-1960.
[10] Han Y,Tang Q,Zhu W, et al. Clinical,biochemical,immunological and virological profiles of,and differential diagnosis between,patients with acute hepatitis B and chronic hepatitis B with acute flare.J Gastroenterol Hepatol, 2008,23:1728-1733. |
